Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes.
Jenkins AJ., Januszewski AS., Kirby A., Hendrieckx C., McAuley SA., Lee MH., Paldus B., Vogrin S., de Bock MI., Abraham MB., Bach LA., Burt MG., Cohen ND., Colman PG., Davis EA., Holmes-Walker DJ., Kaye J., Keech AC., Kumareswaran K., MacIsaac RJ., McCallum RW., Sims CM., Speight J., Stranks SN., Sundararajan V., Trawley S., Ward GM., Jones TW., O'Neal DN., Australian JDRF Closed Loop Research Group None.
Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.